AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02849886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimerizer drug AP1903
Description: AP1903 drug will be administrated at a dose of 0.4 mg/kg by intravenous route in the two following cases:~* Acute Grade ≥II or symptomatic Grade I GvHD justifying systemic immunosuppression therapy;~* Grade ≥3 toxicity attributable to GMC.
Study NCT02594059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endothelial function
Description: measure of reactive hyperemia-peripheral artery tone index
Study NCT04508647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab will be administered as an intravenous infusion through a dedicated line. All infusions will be administered per institutional guidelines.~During ublituximab monotherapy (initial treatment), Cycle 1 Day 1 administration time frame: Over 4 hours. Cycle 1 days 8 and 15 will be over 3 hours, and Cycle 1 Day 22 will be over 90 minutes. During combination treatment with umbralisib, ublituximab will be administered over 90 minutes.
Study NCT04508647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Umbralisib will be administered orally once daily within 30 minutes of starting a meal.
Study NCT02830399 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active rTMS-ECT
Description: 5 High Frequency (20Hz) rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
Study NCT02830399 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham rTMS-ECT
Description: 5 sham rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
Study NCT02425735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK cells
Description: DC-CIK cells will be used against tumor cells.
Study NCT02425735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T cells
Description: γδ T cells will be used against breast tumor.
Study NCT02425735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T/DC-CIK cells
Description: γδ T/DC-CIK cells will be used against breast tumor.
Study NCT03915626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine (RLD) transdermal patch
Description: brand name patch
Study NCT03915626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine (generic) transdermal patch
Description: generic patch
Study NCT03166488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE).
Study NCT03287115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broccoli consumption
Description: All subjects will eat broccoli on day 11
Study NCT04117542 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational data will be obtained through participant self-response, parental response, cognitive performance, and neural imaging.
Study NCT01901016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jacobson progressive muscular relaxation
Description: PMR involves learning to identify the tension in specific muscle groups by tightening and relaxing each muscle group. It includes three different exercises: 1) contraction-relaxation of 12 large muscle groups in the arms, legs, and trunk; 2) identification and relaxation of tensions without the need for movement or contractions; and 3) contraction-relaxation of 12 small muscle groups in the neck, eyes, and mouth
Study NCT01901016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schultz's autogenic training
Description: AT is a relaxation technique that is based on body attitude, reduction of exterior stimulation, inner concentration, and mental repetition of verbal formulas \[28\]. These formulas are organized into six exercises: 1) heaviness; 2) warmth; 3) calm and regular heart function; 4) self-regulation of respiration; 5) warmth in the upper abdominal area; and 6) agreeable cooling of the forehead.
Study NCT00869310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant + dexamethasone
Description: Dexamethasone 8 mg orally: 24 hours after chemotherapy (day 2) and then at 8 am on days 3-4 plus Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.
Study NCT00869310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide + dexamethasone
Description: dexamethasone 8 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on days 3-4 plus Metoclopramide 20 mg orally 4 times a day: 24 hours after chemotherapy and then at 4 pm, 7 pm, 10 pm on day 2 then at 7 am, 12 am, 5 pm, 10 pm on days 3-4.
Study NCT03190785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benzoic acid washout and exposure
Description: see above
Study NCT01277432 — intervention group
Intervention type: OTHER
Intervention: Psychiatrist Interview
Description: Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~* MINI~* SSI-28 (somatization)
Study NCT01277432 — intervention group
Intervention type: OTHER
Intervention: Depression screening - control
Description: All study participants will undergo;~1. a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal~2. a detailed psychological and behavioral assessments using validated questionnaires~3. several specialist questionnaires on depression, self care and quality of life
Study NCT02113007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab plus Temozolomide
Description: Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.
Study NCT03883776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Al18F-NOTA-octreotide
Description: One intravenous injection of 4 MBq/kg
Study NCT03883776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Part 1: Healthy volunteers will undergo consecutive whole-body PET scans, including one low-dose CT, for the first 90 minutes. At 150 ± 15 min and 300 ± 30 min post injection two additional static whole-body PET/CT scans will be acquired.~Part 2: Neuroendocrine tumor patients will undergo a dynamic PET scan for the first 45 minutes, followed by 3 static whole-body PET/CTs at 60 ± 10 min, 120 ± 30 min and 180 ± 30 min post injection.
Study NCT03883776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous blood samples
Description: Blood samples will be obtained for laboratory safety evaluation for initial screening and safety evaluation after injection. Furthermore, venous blood samples will be obtained for metabolite analysis and activity measurements (only for patients) at various time points post injection (5 ± 2 min, 10 ± 5 min, 20 ± 10 min, 40 ± 20 min, 60 ± 30 min, 120 ± 60 min).
Study NCT02686814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 17mm MDT-2215 aortic valve bioprosthesis
Study NCT02311933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoxifen Hydrochloride
Description: Given PO
Study NCT02311933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02311933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02311933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO
Study NCT01767311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab 2.5 mg/kg
Description: 2.5 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
Study NCT01767311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab 5.0 mg/kg
Description: 5.0 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
Study NCT01767311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab 10 mg/kg
Description: 10 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion.
Study NCT01767311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab 5.0 mg/kg
Description: 5.0 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
Study NCT01767311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab 10 mg/kg
Description: 10 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
Study NCT01767311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: biweekly (once every 2 weeks) administered as i.v. infusion
Study NCT01767311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab 10 mg/kg
Description: 10 mg/kg biweekly (once every 2 weeks), once every 4 weeks (Q4W) or once every 3 months (Q3M) i.v. infusion.
Study NCT03965923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine (DPV) Vaginal Ring (VR)
Description: Vaginal ring containing 25 mg of DPV
Study NCT03965923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada Tablet
Description: Tablet taken orally
Study NCT02531126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC1063
Study NCT04729686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Block
Description: Per Standard Institutional Practice
Study NCT04729686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fascia Iliaca Nerve Block
Description: Per Standard Institutional Practice
Study NCT04071236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT04071236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04071236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04071236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT04071236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT04071236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04071236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04071236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04071236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04071236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peposertib
Description: Given PO
Study NCT04071236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO
Study NCT04071236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04071236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04071236 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study NCT04071236 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study NCT03547258 — intervention group
Intervention type: GENETIC
Intervention: Clinical and Molecular data collection
Description: Clinical and Molecular data collection at diagnosis, during treatment and at each relapse
Study NCT00082186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: Oral bosentan tablets 62.5 mg twice daly for 4 weeks, then 125 mg twice daily for 20 weeks.
Study NCT04416919 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assembled mask
Description: Assembled masks consisting of 3 parts: A facemask (Respironics Performax Whole Face Mask or Hans Rudolph mask naso-oral mask) linked by a blue elbow ( RP Performax SE ELBOW) to a ventilator filter (Teleflex Bacterial/Viral filter 1605 or Iso-Gard HEPA light Filter 28022)
Study NCT02328482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tehalose 30gr
Description: Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
Study NCT01677182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon tablets for sublingual administration
Study NCT01677182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets for sublingual administration
Study NCT02706769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study medication contains blinded placebo
Study NCT02706769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Study medication contains blinded paracetamol
Study NCT02501161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
Study NCT02501161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
Study NCT04027179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate mouthwash
Description: 0.12% chlorhexidine digluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
Study NCT04027179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal instrumentation
Description: Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.
Study NCT04027179 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal instrumentation
Description: Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.
Study NCT04027179 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periodontal instrumentation
Description: Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.
Study NCT04027179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
Study NCT02135016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Description: epidural anesthesia with 1% lidocaine 10ml before propofol TCI
Study NCT02135016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Description: epidural anesthesia with 2% lidocaine 5ml before propofol TCI
Study NCT02135016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
Study NCT00824655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13vPnC
Description: 13vPnC will be administered by intramuscular injection at approximately 5 and 12 months of age.
Study NCT00824655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13vPnC
Description: 13vPnC will be administered by intramuscular injection at approximately 12 months of age.
Study NCT01718587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation through interventional procedure
Description: interventional procedure once
Study NCT01718587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antiviral therapy (lamivudine, other antiviral drugs)
Description: lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
Study NCT03451955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Description: Participants in the intervention group abstain from gluten for 6 months.
Study NCT03504189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PregSense™
Description: PregSense™ wearable device will be applied for maternal-fetal monitoring
Study NCT03504189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiotocopraphy (CTG)
Description: Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring
Study NCT02796521 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dietary counseling
Description: Patients received individualized nutritional counseling encouraging them for enrichment
Study NCT02796521 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: nutritional workshop with enrichment during a meal
Description: Patients received in group nutritional informations for enrichment and are encouraged to try enrichment together during a meal.
Study NCT03286621 — intervention group
Intervention type: OTHER
Intervention: Administration of five eye-tracking paradigms
Description: All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.
Study NCT01398657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Androgen-Deprivation Therapy
Description: Short-term adjuvant androgen-deprivation therapy
Study NCT01147562 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of biospecimen
Description: Collection of saliva, blood and tissues from subjects diagnosed with lung cancer, who are scheduled for biopsy of their lesion or surgical resection of their tumor.
Study NCT02662335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Cognitive Training
Description: Participate in Cogmed computerized working memory training
Study NCT02662335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02662335 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02662335 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-Up Care
Description: Undergo standard follow-up care
Study NCT02187237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YOLO TOUCH Low Level Laser
Study NCT01240902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Description: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Study NCT01240902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Aortic Valve Replacement (SAVR)
Description: Surgical Aortic Valve Replacement (SAVR)
Study NCT03020277 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ecological Momentary Assessment with Smartphone© Application
Description: Filling of the application every 3 days for 6 months by subjects (parents of patients with ASD)
Study NCT04356599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early dynamic 18F-FDG PET/CT assessment of cerebral glucose uptake
Description: The intervention will consist in a dynamic cerebral 18F-FDG PET study performed at D2+/-1. Kinetic modeling will be performed using in-house software at the global, regional, and voxel level. In addition, cerebral perfusion and blood-brain-barrier permeability will be assessed at D4+/- 1 using perfusion MRI and permeability MRI.
Study NCT03845621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Mouthguard
Description: Use of a conventional custom-made mouthguard while playing water polo
Study NCT03845621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal-adjusted Mouthguard
Description: Use of an occlusal-adjusted custom-made mouthguard while playing water polo
Study NCT00583011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Local anesthesia: 2 cc of 1% Lidocaine
Study NCT00583011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Placebo Group: 2cc Normal Saline
Study NCT02358265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Rupatadine on demand
Description: Group A1 (dose administered: 10 mg rupatadine on demand): one tablet of placebo once daily- one on-demand tablet of rupatadine 10 mg intake only if needed.
Study NCT02358265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Rupatadine
Description: Group B1 (dose administered: 10 mg rupatadine continuously): one tablet of rupatadine 10 mg once daily, one on-demand tablet of placebo, intake only if needed.
Study NCT02358265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mg Rupatadine
Description: Group B2 (dose administered: 10 mg rupatadine continuously): two tablets of rupatadine 10 mg daily- one on-demand tablet of placebo , intake only if needed.
Study NCT02358265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Rupatadine on demand (sham updosing to 20 mg)
Description: Group A2 (dose administered: 10 mg rupatadine on demand): two tablets of placebo daily- one on-demand tablet of rupatadine 10 mg ,intake only if needed.